


REMARKS

The amendment to the specification enters the priority information for the present application and does not add new matter. Claims 5, 8, 12, 16, and 17 are currently amended. Claims 19 and 20 are newly added. Support for these claims can be found through the application as filed. No new matter has been added as a result of this preliminary amendment. Upon entry of this amendment, claims 1-20 will be pending. Applicants request that the filing fee be calculated in view of the foregoing amendment.

Applicants have included a Fee Transmittal form authorizing the Director to charge Applicants' deposit account for the appropriate fees. The Director is also hereby authorized to charge any deficiency in the fees filed, asserted to be filed, or which should have been filed herewith or with any paper hereafter filed in this application by this firm to our Deposit Account No. 21-0718.

Respectfully submitted,



Timothy J. Gumbleton, Patent Agent
Registration No. 54,143

Date: May 4, 2006

Pfizer Inc.
Patent Department
7000 Portage Road
Kalamazoo, Michigan 49001

Telephone No. (269) 833-2501 or (269) 833-9500
Telefax No. (269) 833-8897 or (269) 833-2316